Earlier detection could drive $527bn in women’s healthcare spending – report

Earlier detection could generate US$527bn in additional potential US women’s healthcare spending by 2030, according to a Deloitte analysis.

The estimate reflects a scenario in which care becomes more proactive through earlier diagnosis, prevention and better disease management across women’s life stages.

It is not a forecast of guaranteed revenue or healthcare savings.

The Deloitte analysis adapted its Future of Health actuarial modelling approach and used five years of medical and pharmacy claims data covering nearly 60m lives.

Across 22 areas of care, the report highlighted brain health, pelvic health, cardiovascular care, and musculoskeletal and autoimmune conditions as examples of where unmet clinical needs and market demand could converge.

Jen Radin, principal at Deloitte & Touche, said achieving the potential identified in the analysis would require earlier diagnosis and stronger links between treatment, symptom management and prevention.

“It could be constrained if diagnosis remains delayed, care stays fragmented, or emerging tools are not validated, integrated into workflows, and linked to appropriate follow-up,” Radin said.

She said the reproductive years and midlife could provide opportunities to identify accumulating health risks before disease progresses, while more accessible detection could benefit women throughout their lives.

“Digital tools such as wearables, blood-based biomarkers, AI-enabled imaging, remote monitoring and virtual specialty programmes could signal issues and support care at any point,” Radin explained.

The report also highlighted care models that bring together clinical information across specialties, potentially helping healthcare teams identify problems earlier and tailor care to a patient’s stage of life.

Health plans could support this approach by improving access to preventive services including diagnostics, monitoring, virtual specialist care and follow-up, according to the analysis.

A separate long-term analysis suggested that prevention and improved disease management could potentially increase women’s health span by up to 20 years.

Deloitte said the health-span estimate and the US$527bn analysis use different time horizons and modelling inputs.

Digital health companies are also testing ways to move preventive women’s healthcare into the home while maintaining links with clinical services.

In July, Teal Health and UC Davis Health announced a pilot examining how at-home cervical cancer screening could be incorporated into routine health system workflows for women aged 30 to 65 who are due or overdue for screening.

Teal’s sample-collection device received FDA authorisation in May 2025. The pilot is assessing whether the screening pathway can improve participation and integrate with existing care delivery.

“As products become available and treatment options expand, women may engage earlier, spending can shift toward promoting health rather than treating disease, and demand may continue to grow for better solutions,” Radin said.